simply [4:< 16 Years Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3,000 mg/day. For Roweepra tablet dosing in pediatric patients weighing 20 to 40 kg, initiate treatment with a daily dose of 500 mg given as twice daily dosing (250 mg twice daily). Increase the daily dose every 2 weeks by increments of 500 mg to a maximum recommended daily dose of 1,500 mg (750 mg twice daily). For Roweepra tablet dosing in pediatric patients weighing more than 40 kg, initiate treatment with a daily dose of 1,000 mg/day given as twice daily dosing (500 mg twice daily). Increase the daily dose every 2 weeks by increments of 1,000 mg/day to a maximum recommended daily dose of 3,000 mg (1,500 mg twice daily). Levetiracetam Oral Solution, USP Weight-Based Dosing Calculation For Pediatric Patients The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients: Daily dose (mg/kg/day) x patient weight (kg) Total daily dose (mL/day) = 100 mg/mL 2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been studied. 2.4 Dosing for Primary Generalized Tonic-Clonic Seizures Adults 16 Years and Older Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been adequately studied. Pediatric Patients Ages 6 to] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer OWP Pharmaceuticals, Inc. Drug Class Pyrrolidine anticonvulsants Related Drugs pyrrolidine anticonvulsants levetiracetam , Keppra , Keppra XR , Briviact , brivaracetam , Spritam Seizures diazepam , levetiracetam , topiramate , Valium , Topamax , Keppra , primidone , Dilantin , oxcarbazepine , phenobarbital , phenytoin , Trileptal , More... Epilepsy gabapentin , Lyrica , Neurontin , lamotrigine , levetiracetam , Lamictal , Keppra , Depakote , carbamazepine , divalproex sodium , Dilantin , pregabalin , More... Roweepra Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Roweepra Images Roweepra 500 mg (OWP 500 ) View all images getting to know
vital Roweepra cut
EmoticonEmoticon